Modern Chinese Medicine Group Co Ltd posted QQ2 2025 results with modest revenue and earnings momentum, reflecting a cautious growth environment in China’s proprietary Chinese medicines space. Revenue of 64.758 million CNY declined 5.77% year over year, while gross profit rose to 16.19 million CNY, delivering a gross margin of approximately 25.0%. Operating income was 2.03 million CNY (3.13% margin) and net income stood at 2.45 million CNY (3.78% net margin), with EPS of 0.004 for the quarter. Notably, the company maintains very healthy liquidity metrics (current ratio 8.53, quick ratio 7.80, cash ratio 7.09) and an extremely low debt profile (debt ratio ~0.0003). This implies substantial financial flexibility to pursue selective growth initiatives or potential deleveraging of non-core structures, should opportunities arise. The quarterly results show a meaningful divergence between top-line trends and profitability, underscored by a sharp year-over-year decline in operating income (−77.8%) and net income (−70.3%), while EBITDA remained positive at 6.56 million CNY and EBITDA margin near 10%. Absent a publicly disclosed earnings call transcript, management commentary for QQ2 2025 remains unavailable in this dataset, limiting the ability to quote specific guidance or color on strategy. Nevertheless, the balance of indicators suggests a cash-rich, low-leverage framework with latent growth opportunities in elderly-care diagnostics, distribution expansion, and expansion of proprietary Chinese medicines across mainland China.